Samarth Kumar
Samarth Kumar has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Krutika K. Sawant
Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India
7 shared publications - Prachi Pandey
Krishna School of Pharmacy & Research, KPGU, Vadodara, Gujarat, India
5 shared publications - Ajay Jaysingh Khopade
Formulation Research and Development, Sun Pharmaceutical Industries Ltd. Tandalja, Vadodara, India
4 shared publications Ajay Khopade
Formulation Research & Development-Non Orals, Sun Pharmaceutical Industries Ltd, Vadodara, India
4 shared publications- Ashay Jain
Formulation Research & Development –Non Orals, Sun Pharmaceutical Industries Ltd, Vadodara, 390020, Gujrat, India
3 shared publications Milan Vasoya
Formulation Research & Development-Non Orals, Sun Pharmaceutical Industries Ltd, Vadodara, India
3 shared publications
Latest Publications
- Open Access
- 8 October 2025
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 1 (1) , 1-31
Unlocking norepinephrine potential innovations in formulation and smart systems
- 8 October 2025
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 1 (1) , 1-31
Open AccessUnlocking norepinephrine potential innovations in formulation and smart systems
- 29 July 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (8) , 619-637
Application of sphingolipid-based nanocarriers in drug delivery: an overview
Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer's disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.
- 29 July 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (8) , 619-637
Application of sphingolipid-based nanocarriers in drug delivery: an overview
Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer's disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.
- 15 March 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 95
USFDA-approved parenteral peptide formulations and excipients: Industrial perspective
- 15 March 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 95
USFDA-approved parenteral peptide formulations and excipients: Industrial perspective
- 13 January 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 652, 123785
Glucagon: Delivery advancements for hypoglycemia management
- 13 January 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 652, 123785
Glucagon: Delivery advancements for hypoglycemia management
- 12 January 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 92
Emerging therapeutic landscape on delivery of oxytocin to brain for treating neurological disorders
- 12 January 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 92
Emerging therapeutic landscape on delivery of oxytocin to brain for treating neurological disorders
- 18 September 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 88, 104969
Nanocarriers mediated delivery of methotrexate is instrumental in treating auto-immune diseases and cancer
- 18 September 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 88, 104969
Nanocarriers mediated delivery of methotrexate is instrumental in treating auto-immune diseases and cancer